a-connect’s business consulting services are designed to help you tackle key business challenges, create real value through transformation and improvements, and plan for the future.
We help you drive improvements across the whole life science organization, from all aspects of strategy and organizational design, to product development, and technical and day-to-day operations. We are also experts at commercial evolution, including new product development, commercial strategies, branding, pricing and market access, sales effectiveness, and loss-of-exclusivity strategies.
Our independent consultants can successfully deliver projects across a wide range of therapy areas, and our expertise includes rare diseases, oncology, cardiovascular and metabolic, respiratory, HIV, ophthalmology, neurology, immunology, and dermatology.
a-connect can also help you expand into new disciplines, bringing valuable knowledge and experience in disciplines like biosimilar manufacturing, cell and gene therapy, the connected health experience, and multichannel marketing. In addition, we bring a wealth of expertise in healthcare service development, including health insurance, new payment models and point-of-care diagnostics.
Facilitating a smooth international business acquisition
When a Europe-based biopharma client acquired a business unit from another global company, they needed support from a trusted, experienced partner with global reach in order to seamlessly integrate the new unit at regional and local levels.
Strategic planning for specialty pharma in emerging markets
Against a backdrop of new competition, volatile market conditions, and policy changes, our client’s emerging market region was seeking investment to deliver faster-than-market growth across emerging markets.
Acceleration of a large-scale multi-therapeutic area (TA) launch
Our client, a big pharma company, had recently seen breakthrough results in a large clinical trial for a new drug. These results positioned them well ahead of the competition in terms of launching new indications. As a result, the therapeutic area team found themselves with a narrow window in which to capitalize on the opportunity presented by the clinical evidence.
Optimizing reductions in cost of goods sold (COGS)
The client, a leading life sciences firm, was in a tough position. Operating in extremely competitive markets for top-10 molecules, and with COGS at unsustainable levels, the company was struggling to remain competitive—let alone plan for future growth.
Identifying opportunities to increase revenues for a large portfolio of mature product
Our client had a large portfolio of mature products, available across more than 20 countries, which were no longer actively marketed. In many cases, the price of these mature products had not been reviewed or amended for several years.